Overview of Psoralen-UVA in Psoriasis Treatment

Authors

  • Tachsinee Kanchanaalongkorn Pharmacy Department, Ramathibodi Hospital

Keywords:

psoriasis, PUVA, psoralen, 8-methoxypsoralen

Abstract

The treatment of moderate to severe psoriasis by psoralen in combination with ultraviolet A irradiation (PUVA) was considered to be effective and safe. It is suitable for patients who need more effective treatment than topical therapy and avoidance of systemic medication. PUVA is indicated in patients who do not respond to narrow band-UVB. There are four mechanisms of action of PUVA: 1) alteration of cytokine profile 2) induction of apoptosis 3) promotion of immunosuppression 4) other additional mechanisms. PUVA has long-term adverse events in photocarcinogenesis, most likely due to oral psoralen in PUVA. The topical dosage form is therefore a good alternative as it has fewer side effects and is suitable for the treatment of localized psoriasis. Preparing a quality psoralen solution for patients is important because it affects the effectiveness of the treatment and in order to alleviate the symptoms of the disease and increase the overall quality of life for the patients to have normal daily living.

Author Biography

Tachsinee Kanchanaalongkorn, Pharmacy Department, Ramathibodi Hospital

Pharm.D.

References

Li L, Taliercio M, Hashim PW, Kimmel G, Nia JK. Palmoplantar psoriasis: a review of topical therapies. Glob Dermatol. 2016;3(6):387-93. doi: 10.15761/GOD.1000196.

เบ็ญจ์สชีว์ ปัทมดิลก. โรคสะเก็ดเงิน Psoriasis [อินเทอร์เน็ต]. กรุงเทพมหานคร: สถาบันโรคผิวหนัง กรมการแพทย์; 2561 [สืบค้นเมื่อ 20 ธ.ค. 2565]. สืบค้นจาก: https://www.iod.go.th/wp-content/uploads/2020/10/news_29.pdf

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042.

Ibbotson SH. A perspective on the use of NB-UVB phototherapy vs. PUVA photochemotherapy. Front Med. 2018;5:184. doi: 10.3389/fmed.2018.00184.

Ling TC, Clayton TH, Crawley J, Exton LS, Goulden V, Ibbotson S, et al. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015. Br J Dermatol. 2016;174(1):24-55. doi: 10.1111/bjd.14317.

Debta FM, Ghom A, Debta P, Deoghare A. Photochemotherapy (PUVA): an overview. J Indian Acad Oral Med Radiol. 2010;22(3):141-3. doi: 10.5005/jp-journals-10011-1033.

Delrosso G, Savoia P. Effectiveness and safety of topical phototherapy in the treatment of dermatological diseases. In: Tanaka Y, editor. Photomedicine - advances in clinical practice. London: InTechOpen; 2017. p. 137-152. doi: 10.5772/65712.

Pai S, Shetty S. Guidelines for bath PUVA, bathing suit PUVA and soak PUVA. Indian J Dermatol Venereol Leprol. 2015; 81(6):559-67. doi: 10.4103/0378-6323.168336.

Diekmann J, Theves I, Thom KA, Gilch P. Tracing the photoaddition of pharmaceutical psoralens to DNA. Molecules. 2020;25(22):5242. doi: 10.3390/molecules25225242.

Wong T, Hsu L, Liao W. Phototherapy in psoriasis: a review of mechanisms of action. J Cutan Med Surg. 2013;17(1):6-12. doi: 10.2310/7750.2012.11124.

LiverTox®. Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. PMID: 31643176.

USP 29. Methoxsalen topical solution [Internet]. Rockville, MD: United States Pharmacopeial Convention Incorporated; 2006 [cited 2022 Dec 20]. Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_m51660.html

U.S. Pharmacopeia. Proposed revisions to USP general chapter (795) Pharmaceutical compounding – nonsterile preparations [Internet]. Rockville, MD: United States Pharmacopeial Convention Incorporated; 2022 [cited 2022 Dec 20]. Available from: https://www.usp.org/sites/default/files/usp/document/stakeholder-forum/795-open-forum-01-12-2022.pdf

USP 29. Methoxsalen [Internet]. Rockville, MD: United States Pharmacopeial Convention Incorporated; 2006 [cited 2022 Dec 20]. Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_m51640.html

USP 29. Reference tables: description and solubility - M [Internet]. Rockville, MD: United States Pharmacopeial Convention Incorporated; 2006 [cited 2022 Dec 20]. Available from: http://www.pharmacopeia.cn/v29240/usp29nf24s0_alpha-2-22.html

Rowe RC, Sheskey PJ, Quinn ME, editors. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press and the American Pharmacists Association; 2009.

Honigsmann H, Fitzpatrick TB, Pathak MA, Wolff K. Oral photochemotherapy with psoralen and UVA (PUVA): principles and practice. In: Fitzpatrick TB, Eisen AZ, Wolf K, editors. Dermatology in general medicine. New York: McGraw-Hill; 1987. p. 1728-54.

Wu JH, Jones NJ. Assessment of DNA interstrand crosslinks using the modified alkaline comet assay. Methods Mol Biol. 2012;817:165-81. doi: 10.1007/978-1-61779-421-6_9.

Downloads

Published

2023-12-31

How to Cite

1.
Kanchanaalongkorn T. Overview of Psoralen-UVA in Psoriasis Treatment. Thai J Hosp Pharm [internet]. 2023 Dec. 31 [cited 2026 Jan. 5];33(3):446-60. available from: https://he02.tci-thaijo.org/index.php/TJHP/article/view/264923

Issue

Section

Continuing Pharmaceutical Education